Author(s): Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK, Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK, Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK, Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK
Abstract Share this page
Abstract Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
This article was published in Nature
and referenced in Immunotherapy: Open Access